[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Prenosis, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,38],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100644886","observational-non-interventional-biomarker-and-endotyping-study-100644886",false,"NCT07675265","Observational, Non-interventional Biomarker and Endotyping Study","Observational Biomarker Study for the Evaluation of Response and Validation of Endotypes in Acute Respiratory Distress Syndrome","OBSERVE-ARDS","Inclusion Criteria:\n\n* Age ≥18 years\n* ARDS Diagnosis (New Global Definition of ARDS)\n* Timing: Acute onset within 7 days\n* Radiology: Bilateral pulmonary opacities\n* Hypoxia:\n\nNon-intubated ARDS: PaO2:FIO2\\\u003C300mmHg or SpO2:FIO2\\\u003C315 (if SpO2\\\u003C97%) on HFNO with flow of \\>30 L\u002Fmin or NIV\u002FCPAP with at least 5 cm H2O end-expiratory pressure; or Intubated ARDS: PaO2:FIO2\\\u003C300 mm Hg or SpO2:FIO2\\\u003C315 (if SpO2\\\u003C97%)\n\n* ICU admission\n* Enrolled within 72 hours of meeting inclusion criteria\n\nExclusion Criteria:\n\n• Primary cardiogenic pulmonary edema","ALL","18 Years",{"count":20,"type":21},1200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to establish a centralized ARDS biorepository of longitudinal biospecimens and harmonized clinical data, develop unsupervised, therapy-agnostic endotyping algorithms, and develop unsupervised, therapy-specific treatment-prediction algorithms over a 24 month period.",[25],"ARDS (Acute Respiratory Distress Syndrome)","NOT_YET_RECRUITING","2026-06-23",{"date":29,"type":30},"2026-06-30","ACTUAL",{"date":32,"type":21},"2026-07",{"date":34,"type":21},"2029-03",{"name":36,"class":37},"Prenosis, Inc.","INDUSTRY",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":4},"100634731","performance-and-impact-of-the-sepsis-immunoscore-100634731","NCT07543497","Performance and Impact of the Sepsis ImmunoScore","Clinical Utility and Performance of the Sepsis ImmunoScore: A Prospective Cohort Device Study","Inclusion Criteria:\n\n* Adult (age 18 years or older) patients presenting to hospitals and emergency departments of medical institutions across the United States.\n* Adult (age 18 years or older) patients suspected of sepsis.\n\nExclusion Criteria:\n\n* none",{"count":46,"type":21},5000,"The goal of this prospective cohort device study is to assess clinical usage and impact, diagnostic performance, and prognostic performance of the Sepsis ImmunoScore.",[49],"Sepsis",[51],"sepsis","2026-04-15",{"date":54,"type":30},"2026-04-22",{"date":56,"type":21},"2026-04",{"date":58,"type":21},"2027-12",{"name":36,"class":37},""]